NCT05757492View on ClinicalTrials.gov

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 26, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Advanced Solid TumorNon-Small Cell Lung CancerHepatocellular Carcinoma
Interventions
DRUG

CHS-006 (anti-TIGIT)

Arm A participants will receive CHS-006 administered via IV Q3W.

DRUG

toripalimab (anti-PD-1)

Arm B participants will receive toripalimab administered via IV Q3W.

Trial Locations (4)

32806

University of Florida Health Cancer Center, Orlando

44718

Gabrail Cancer and Research Center, Canton

48201

Barbara Ann Karmanos Cancer Institute, Detroit

89502

Renown Institute for Cancer, Reno

Sponsors

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

collaborator

Shanghai Junshi Bioscience Co., Ltd.

OTHER

lead

Coherus Oncology, Inc.

INDUSTRY

NCT05757492 - Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter